|
|
| (2 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | |
| |authorTag=HAFIZA AMNA QADEER
| |
| |OTC=Yes
| |
| |genericName=REZAFUNGIN
| |
| |aOrAn=an
| |
| |drugClass=ANTIFUNGAL ECHINOCANDIN
| |
| |indicationType=treatment
| |
| |indication=patients with invasive candidiasis and candidemia who are at least 18 years old and have few or no other options for treatment.
| |
| |adverseReactions=Diarrhea, vomiting, nausea, abdominal pain, constipation, hypokalemia, hypomagnesemia, hypophosphatemia, pyrexia and anemia.
| |
| |fdaLIADAdult=The recommended dosage of rezafungin is once weekly by intravenous (IV) infusion, with an initial 400 mg loading dose, followed by a 200 mg dose once weekly thereafter. The safety of rezafungin has not been established beyond 4 weekly doses. Rezafungin is used for intravenous infusion only. Administer rezafungin by intravenous infusion over approximately one hour (~250 mL/h). If infusion-related reactions occur, the infusion may be slowed, or paused and restarted at a lower rate.
| |
| |contraindications=Rezafungin is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.
| |
| |clinicalTrials=The following adverse reaction can occur after administration of rezafungin:
| |
| =GASTROINTESTINAL=
| |
| Diarrhea, Nausea, Vomiting, Dysphagia, Gastrointestinal hemorrhage, abnormal liver tests (including hypertransaminasemia and increased gamma-glutamyltransferase), abdominal pain and constipation.
| |
| =METABOLISM AND NUTRITION DISORDER=
| |
| Anemia, Disseminated Intravascular Coagulation.
| |
| =NERVOUS SYSTEM=
| |
| Tremor, insomnia, headache, dizziness, peripheral neuropathy (includes neuropathy peripheral, polyneuropathy, and peroneal nerve palsy).
| |
| =INTEGUMENTARY SYSTEM=
| |
| Photosensitivity and erythema.
| |
| =CARDIOVASCULAR SYSTEM=
| |
| Fluid overload.
| |
| |useInPregnancyFDA=There are no data on the use of rezafungin during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
| |
| |useInNursing=There are no data on the presence of rezafungin or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.
| |
| |useInPed=The safety and effectiveness of rezafungin have not been established in pediatric patients.
| |
| |useInGender=Clinical studies of rezafungin did not include sufficient numbers of older adult patients to determine if patients 65 years and older respond differently than younger adult patients.
| |
| |useInReproPotential=The effect of rezafungin on human fertility is unknown.
| |
| |overdose=No cases of overdose were reported during the clinical studies. Rezafungin is highly protein bound and not anticipated to be dialyzable.
| |
| |brandNames=REZZAYO
| |
| }}
| |